KR20220119731A - 장기 지속형 glp-1 화합물 - Google Patents

장기 지속형 glp-1 화합물 Download PDF

Info

Publication number
KR20220119731A
KR20220119731A KR1020227026310A KR20227026310A KR20220119731A KR 20220119731 A KR20220119731 A KR 20220119731A KR 1020227026310 A KR1020227026310 A KR 1020227026310A KR 20227026310 A KR20227026310 A KR 20227026310A KR 20220119731 A KR20220119731 A KR 20220119731A
Authority
KR
South Korea
Prior art keywords
oeg
human insulin
γglu
desb30 human
eicosandioyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227026310A
Other languages
English (en)
Korean (ko)
Inventor
종루 간
웨이 천
이닝 장
팡카이 슈에
링위 차이
지앙홍 니우
빈 무
Original Assignee
간 앤 리 파마슈티칼스 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 filed Critical 간 앤 리 파마슈티칼스 컴퍼니, 리미티드
Publication of KR20220119731A publication Critical patent/KR20220119731A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pens And Brushes (AREA)
  • Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
KR1020227026310A 2019-12-30 2020-12-29 장기 지속형 glp-1 화합물 Pending KR20220119731A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911397405.2 2019-12-30
CN201911397405 2019-12-30
CN202011053306 2020-09-29
CN202011053306.5 2020-09-29
PCT/CN2020/141057 WO2021136303A1 (zh) 2019-12-30 2020-12-29 长效glp-1化合物

Publications (1)

Publication Number Publication Date
KR20220119731A true KR20220119731A (ko) 2022-08-30

Family

ID=76687327

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227026310A Pending KR20220119731A (ko) 2019-12-30 2020-12-29 장기 지속형 glp-1 화합물

Country Status (10)

Country Link
US (2) US20240239859A1 (enExample)
EP (1) EP4086277A4 (enExample)
JP (1) JP2023510218A (enExample)
KR (1) KR20220119731A (enExample)
CN (5) CN119060162A (enExample)
AU (1) AU2020418207A1 (enExample)
BR (1) BR112022013042A2 (enExample)
CA (1) CA3166496A1 (enExample)
MX (1) MX2022008139A (enExample)
WO (1) WO2021136303A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025005743A1 (ko) * 2023-06-30 2025-01-02 주식회사 휴온스랩 Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
US20250115654A1 (en) * 2021-11-12 2025-04-10 Fujian Shengdi Pharmaceutical Co., Ltd. Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
US20250340610A1 (en) * 2022-01-28 2025-11-06 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN121219311A (zh) * 2023-05-24 2025-12-26 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
WO2025098415A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于降糖的glp-1化合物
WO2025098416A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于减肥的glp-1化合物
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
CA2572770A1 (en) * 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US9150633B2 (en) * 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) * 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8788849B2 (en) * 2011-02-28 2014-07-22 Sandisk Technologies Inc. Method and apparatus for protecting cached streams
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
EP3922260A3 (en) * 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
PE20210857A1 (es) * 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
EP4086277A4 (en) * 2019-12-30 2024-02-14 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025005743A1 (ko) * 2023-06-30 2025-01-02 주식회사 휴온스랩 Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20250011385A1 (en) 2025-01-09
CN119529057A (zh) 2025-02-28
CN119060161A (zh) 2024-12-03
BR112022013042A2 (pt) 2022-10-18
MX2022008139A (es) 2022-10-03
CA3166496A1 (en) 2021-07-08
CN119060163A (zh) 2024-12-03
JP2023510218A (ja) 2023-03-13
WO2021136303A1 (zh) 2021-07-08
CN114901680A (zh) 2022-08-12
EP4086277A1 (en) 2022-11-09
AU2020418207A1 (en) 2022-08-25
CN114901680B (zh) 2024-09-27
US20240239859A1 (en) 2024-07-18
CN119060162A (zh) 2024-12-03
EP4086277A4 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
US20250011385A1 (en) Long-Acting GLP-1 Compound
US20250032589A1 (en) Insulin Derivative
JP2023510218A5 (enExample)
JP2023510206A5 (enExample)
JP2023510219A5 (enExample)
US20250340610A1 (en) Acylated insulin
EA050234B1 (ru) Препараты glp-1 длительного действия
HK40115534A (zh) 长效glp-1化合物
EA050813B1 (ru) Производное инсулина
HK40070502A (zh) 胰岛素衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000